• Home
  • Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

Author List
Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/79295551
Publication Year
2018
Publication Title
Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):10536-10536.